GLP-1 Medications Explained: UK & US Options in 2026

Medication Management cover: GLP-1 medications explained

By Orla Rose · Evidence checked 13 September 2026 · For adult UK and US readers

It is easy to feel behind when the conversation changes from Ozempic to Mounjaro to a new tablet before you have worked out the first name. Add a US podcast to a UK pharmacy website and the confusion is quite understandable.

The useful starting point is the box in front of you: its brand, active ingredient, formulation and the reason it was prescribed. Those details matter more than the umbrella phrase “weight-loss jab”. This guide focuses on adult treatment. Children and adolescents have separate eligibility and specialist-care considerations.

How do these medicines work?

GLP-1 stands for glucagon-like peptide-1, a hormone involved in the body's response to food. Medicines acting at its receptor can influence appetite and help regulate blood glucose. Several also delay stomach emptying. Tirzepatide acts at both the GLP-1 and glucose-dependent insulinotropic polypeptide, or GIP, receptors. MHRA overview; tirzepatide prescribing information.

In everyday life, some people find food takes up less mental space or a familiar portion feels larger. Your experience may be different. Having no dramatic appetite sensation does not establish that treatment is ineffective, and being unable to eat is not a goal.

The prescription still needs to fit your health, other medicines and ability to manage food and fluids. “It works on appetite” is an explanation of one effect, not a complete account of your nutritional needs or a reason to dismiss side effects.

Which names mean what in the UK and US?

Main brands and adult prescribing distinctions, checked 13 September 2026
Brand and ingredient	Form	UK context	US context
Wegovy — semaglutide	Weekly injection; daily tablet	Weight-management indications. Tablet and injection have their own labels.	Weight-management indications. Other indications depend on the formulation and patient group.
Ozempic — semaglutide	Weekly injection	Type 2 diabetes medicine; not the Wegovy weight-management licence.	Type 2 diabetes, with additional cardiovascular and kidney-risk indications for specified adults with type 2 diabetes.
Mounjaro — tirzepatide	Weekly injection	Type 2 diabetes and weight management.	Type 2 diabetes; also cardiovascular-risk reduction for specified adults with type 2 diabetes. Zepbound is the US weight-management brand.
Zepbound — tirzepatide	Weekly injection	The relevant UK weight-management brand is Mounjaro.	Chronic weight management; also moderate-to-severe obstructive sleep apnoea in adults with obesity.
Saxenda — liraglutide	Daily injection	Weight management.	Chronic weight management.

This is a guide to the main adult distinctions, not a complete list of each product's indications, age limits or contraindications. Approval does not guarantee stock or funded access. Sources: UK Wegovy injection, UK Wegovy tablets, US Wegovy, MHRA brand overview, US Ozempic, UK Mounjaro, US Mounjaro, US Zepbound, UK Saxenda and US Saxenda.

That means “I take Mounjaro” can describe different approved prescribing contexts on either side of the Atlantic. It also means a video showing an American injection device may be the wrong demonstration for your pack. Ask your pharmacist to show you your exact device and let you explain the steps back.

Are GLP-1 tablets an option now?

Yes. An account of GLP-1 weight-management treatment as injections only is out of date. Wegovy tablets have UK and US authorisations. The MHRA announced the UK tablet approval on 11 June 2026 for eligible adults. Read the UK approval announcement; current US Wegovy label.

In the US, the FDA approved Foundayo, containing orforglipron, on 1 April 2026 for weight management in eligible adults alongside diet and physical activity. It is a daily tablet and does not require the empty-stomach routine used for oral semaglutide. That FDA decision establishes US approval; it does not establish UK access. Read the FDA decision.

A tablet may sound easier if needles put you off, but the practical comparison includes how it is taken. Oral semaglutide has specific fasting, water and waiting instructions. Foundayo has different administration instructions. Read the leaflet supplied with your prescription and ask how it fits around breakfast and other medicines. UK Wegovy tablet instructions; Foundayo prescribing information.

Do not convert an injection dose into a tablet dose yourself. The numbers on the packs are not a simple equivalence calculation. A formulation change needs a prescriber's plan.

What does the newer higher-dose Wegovy mean?

The FDA approved the 7.2 mg weekly Wegovy HD injection on 19 March 2026. Current UK Wegovy injection information also includes a 7.2 mg option for certain adults with obesity. This expands treatment options under clinical supervision; it does not make the highest number the appropriate starting point or target for everyone. FDA approval announcement; UK prescribing information.

When you see a weight-loss headline, check which dose and formulation were tested. A result for the older 2.4 mg injection cannot stand in for a newer dose or a tablet, even when the brand name is familiar.

Which medicine produces more weight loss?

One direct comparison provides a useful answer to a narrow question. SURMOUNT-5 randomly assigned 751 adults with obesity and without type 2 diabetes to tirzepatide or semaglutide for 72 weeks. Treatment used maximum tolerated tirzepatide doses of 10 or 15 mg and semaglutide doses of 1.7 or 2.4 mg.

SURMOUNT-5: mean percentage change in body weight at 72 weeks
Treatment	Mean change	95% confidence interval
Tirzepatide	−20.2%	−21.4% to −19.1%
Semaglutide	−13.7%	−14.9% to −12.6%

The difference was 6.5 percentage points. This was an open-label trial, so participants and investigators knew the allocated treatment, and Lilly funded it. The findings concern those doses and that population. They do not compare tirzepatide with semaglutide 7.2 mg or the tablets, establish results in people with diabetes, or predict what an individual will lose. Read the original New England Journal of Medicine report.

Percentages describe a proportion of starting weight. As a simple arithmetic example, 10% of 100 kg is 10 kg; 10% of 220 lb is 22 lb. Neither example is a treatment forecast. A trial average also tells you little about whether you can tolerate a medicine, obtain it reliably or afford ongoing care.

What should you know about side effects before choosing?

Nausea, vomiting, diarrhoea and constipation feature in the product information for these treatments. More serious problems are also described. Your prescriber should discuss the relevant warnings and your history, including significant digestive problems, other medicines and pregnancy or pregnancy plans. MHRA patient guide.

For US readers, labels carry thyroid C-cell tumour warnings and restrictions concerning a personal or family history of medullary thyroid carcinoma or MEN2. The warning is based on animal findings; it does not mean the medicine has been shown to cause this cancer in humans. Bring the specific family diagnosis to your clinician rather than treating every thyroid condition as the same. US Ozempic warning and contraindications.

Severe, persistent abdominal pain, particularly pain reaching the back, needs urgent assessment. The MHRA strengthened pancreatitis warnings in January 2026. Our symptom guides on nausea, constipation and fatigue cover everyday questions alongside reasons to seek care. They cannot decide whether a medicine is suitable for you. Read the pancreatitis safety update.

Does approval mean the NHS or insurance will pay?

No. Approval, a prescription, pharmacy supply and funding are separate steps. A medicine can be licensed without being funded for your situation. It can be covered in principle while your prescription still needs an assessment or authorisation.

UK: ask which access rules apply in England, Scotland, Wales or Northern Ireland, and through which local service. A private clinic's prescribing eligibility does not establish NHS eligibility. The NHS overview of obesity treatment is a starting point; your own service must confirm the applicable pathway.

US: ask your insurer about the exact brand and indication, prior authorisation, any renewal criteria and the amount you would pay. “GLP-1 covered” is too vague if the policy covers a diabetes indication but excludes weight-management treatment. Request the details for your own plan before relying on a pharmacy's advertised price.

For either country, price the continuing arrangement: medicine, consultations, delivery and what happens if supply or affordability changes. Our GLP-1 cost guide helps organise those questions. A low first payment is only one part of the decision.

What about compounded medicines and research peptides?

In the US, compounded GLP-1 drugs are not FDA-approved products. They do not undergo the same premarket review for safety, effectiveness and quality. The FDA has reported concerns including dosing errors and products with misleading claims. Ask the prescribing clinician and dispensing pharmacist exactly what is being supplied and why. FDA guidance on unapproved GLP-1 drugs.

The same FDA page states that retatrutide and cagrilintide are not components of an FDA-approved drug. Promising research does not turn an online “research peptide” into an approved medicine. A seller's photograph, laboratory certificate or reference to a clinical trial does not establish that its product is the treatment studied.

UK readers should obtain prescription medicines through legitimate prescribing and pharmacy services and follow the MHRA's advice on safe access. A US announcement or an overseas seller cannot confirm what is appropriate or authorised for a UK prescription.

What should you ask at the appointment?

Take the questions that would change your decision. You do not need to memorise every trial acronym.

Why this medicine for me? Ask which diagnosis, risks and treatment goals it addresses.
What is the exact product? Confirm brand, formulation, device and instructions.
What would make us review the plan? Include side effects, difficulty eating, other health measures and your own priorities.
Who helps between appointments? Know the contact route for symptoms, supply problems and questions.
Can I obtain and afford continuing treatment? Confirm the access pathway rather than relying on a headline price.
How will food, strength and daily life be supported? Ask about dietetic or other help where needed.

You can also say what you are worried about: injections, losing enjoyment of food, insurance changes, a family history or the prospect of long-term treatment. Those concerns belong in the decision. A medicine can have strong evidence and still need careful discussion about how it fits your life.

What else do readers ask?

Are Ozempic and Wegovy the same?

They share semaglutide, but their approved uses, formulations and dosing instructions differ. Use the label for the product prescribed to you. Do not substitute one using advice meant for the other.

Are Mounjaro and Zepbound the same?

They share tirzepatide. Mounjaro has a UK weight-management indication; in the US, Zepbound is the weight-management brand. The brand, country and supplied device still matter.

Will you need treatment forever?

Some people use weight-management medication long term. Duration depends on benefit, tolerability, health and access, with regular review. No habit plan can guarantee that weight will stay unchanged after stopping. Our guide to weight regain after stopping explains the evidence and planning questions. NIDDK on treatment duration.

Can you combine two GLP-1 products for a stronger effect?

Do not add another product yourself. Labels contain restrictions on combining these medicines. Your prescriber needs to know everything you take, including an online or compounded product.

Sources

References are linked beside the relevant information in this article.